HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

NF023

the symmetrical 3'-urea of 8-(benzamido)naphthalene-1,3,5-trisulfonic acid

Also Known As:

8,8'-(carbonylbis(imino-3,1-phenylene))bis-(1,3,5-naphthalenetrisulfonic acid); NF-023

Networked: 5 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Cossu, Federica: 2 articles (10/2020 - 04/2015)
2.	Mastrangelo, Eloise: 2 articles (10/2020 - 04/2015)
3.	Milani, Mario: 2 articles (10/2020 - 04/2015)
4.	Fagnani, Elisa: 1 article (10/2020)
5.	Giorgino, Toni: 1 article (10/2020)
6.	Sorrentino, Luca: 1 article (10/2020)
7.	Zaffaroni, Mattia: 1 article (10/2020)
8.	Akutagawa, Masatake: 1 article (03/2018)
9.	Emoto, Takahiro: 1 article (03/2018)
10.	Feng, Rui: 1 article (03/2018)

Related Diseases

1.	Neoplasms (Cancer) 03/01/2018 - "The reductive effect of cancer cell viability following blue LED irradiation was reversed by Opn3 knockdown or NF023 treatment. " 04/01/2015 - "Here we report the crystal structure of the human X-BIR1 domain in the absence and in the presence of NF023, as a starting concept for the design of novel BIR1-specific compounds acting synergistically with existing pro-apoptotic drugs in cancer therapy." 10/26/2020 - "NF023 is, thus, a promising protein-protein interaction disruptor, representing a starting point to develop modulators of NF-κB-mediated cell survival in cancer. "
2.	Acute Pain 03/01/2010 - "The rank order of mED values in acute pain was the following: MRS2365 > MRS2395 > NF449 > NF023 > UDP = UTP > PPADS. "
3.	African Trypanosomiasis (Nagana) 01/01/2017 - "This screen identified suramin, a drug used to treat African trypanosomiasis, and its analogues NF023 and NF449 as inhibitors of the SH2 domains of STAT5a/b. "
4.	Pain (Aches) 03/01/2010 - "The effect of the wide spectrum P2 receptor antagonist PPADS, the selective P2X7 receptor antagonist Brilliant Blue G (BBG), the P2X1 receptor antagonist (4,4',4'',4-[carbonylbis(imino-5,1,3-benzenetriyl-bis(carbonylimino))]tetrakis-1,3-benzenedisulfonic acid, octasodium salt (NF449) and (8,8'-[carbonylbis(imino-3,1-phenylenecarbonylimino)]bis-1,3,5-naphthalene-trisulphonic acid, hexasodium salt (NF023), the P2Y12 receptor antagonist (2,2-dimethyl-propionic acid 3-(2-chloro-6-methylaminopurin-9-yl)-2-(2,2-dimethyl-propionyloxymethyl)-propylester (MRS2395), the selective P2Y1 receptor agonist ([[(1R,2R,3S,4R,5S)-4-[6-amino-2-(methylthio)-9H-purin-9-yl]-2,3-dihydroxybicyclo[3.1.0]hex-1-yl]methyl] diphosphoric acid mono ester trisodium salt (MRS2365), the P2Y2/P2Y4 agonist uridine-5'-triphosphate (UTP), and the P2Y4/P2Y6 agonist uridine-5'-diphosphate (UDP) were examined on mechanical allodynia in the Seltzer model of neuropathic pain, on acute thermal nociception, and on the inflammatory pain and oedema induced by complete Freund's adjuvant (CFA). "
5.	Neuralgia (Stump Neuralgia) 03/01/2010 - "The effect of the wide spectrum P2 receptor antagonist PPADS, the selective P2X7 receptor antagonist Brilliant Blue G (BBG), the P2X1 receptor antagonist (4,4',4'',4-[carbonylbis(imino-5,1,3-benzenetriyl-bis(carbonylimino))]tetrakis-1,3-benzenedisulfonic acid, octasodium salt (NF449) and (8,8'-[carbonylbis(imino-3,1-phenylenecarbonylimino)]bis-1,3,5-naphthalene-trisulphonic acid, hexasodium salt (NF023), the P2Y12 receptor antagonist (2,2-dimethyl-propionic acid 3-(2-chloro-6-methylaminopurin-9-yl)-2-(2,2-dimethyl-propionyloxymethyl)-propylester (MRS2395), the selective P2Y1 receptor agonist ([[(1R,2R,3S,4R,5S)-4-[6-amino-2-(methylthio)-9H-purin-9-yl]-2,3-dihydroxybicyclo[3.1.0]hex-1-yl]methyl] diphosphoric acid mono ester trisodium salt (MRS2365), the P2Y2/P2Y4 agonist uridine-5'-triphosphate (UTP), and the P2Y4/P2Y6 agonist uridine-5'-diphosphate (UDP) were examined on mechanical allodynia in the Seltzer model of neuropathic pain, on acute thermal nociception, and on the inflammatory pain and oedema induced by complete Freund's adjuvant (CFA). "

Related Drugs and Biologics

1.	4,4,',4'',4'''- (carbonylbis(imino- 5,1,3- benzenetriylbis(carbonylimino)))tetrakis(benzene- 1,3- disulfonate)
2.	Purinergic P2Y Receptor Antagonists
3.	Purinergic P2X7 Receptors
4.	Purinergic P2X1 Receptors
5.	Purinergic P2Y1 Receptors
6.	Uridine Triphosphate (UTP)
7.	Uridine Diphosphate (UDP)
8.	Uridine
9.	Suramin (Suramin Sodium)
10.	Salts

Related Therapies and Procedures

1.	Therapeutics